Regeneron Pharmaceuticals Inc (REGN) Shares Sold by Ingalls & Snyder LLC

Ingalls & Snyder LLC cut its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 2.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,165 shares of the biopharmaceutical company’s stock after selling 163 shares during the period. Ingalls & Snyder LLC’s holdings in Regeneron Pharmaceuticals were worth $2,318,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. State of Alaska Department of Revenue boosted its position in shares of Regeneron Pharmaceuticals by 638.9% in the fourth quarter. State of Alaska Department of Revenue now owns 9,310 shares of the biopharmaceutical company’s stock worth $3,498,000 after acquiring an additional 8,050 shares during the last quarter. Syntal Capital Partners LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $375,000. Fox Run Management L.L.C. acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $1,110,000. Westpac Banking Corp boosted its position in shares of Regeneron Pharmaceuticals by 5.9% in the fourth quarter. Westpac Banking Corp now owns 17,956 shares of the biopharmaceutical company’s stock worth $6,751,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 5.9% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 284,567 shares of the biopharmaceutical company’s stock worth $106,986,000 after acquiring an additional 15,924 shares during the last quarter. 66.63% of the stock is currently owned by institutional investors and hedge funds.

Shares of Regeneron Pharmaceuticals Inc (NASDAQ REGN) opened at $371.53 on Friday. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. The stock has a market cap of $39,889.95, a price-to-earnings ratio of 32.15, a P/E/G ratio of 1.43 and a beta of 1.53. Regeneron Pharmaceuticals Inc has a 12 month low of $340.09 and a 12 month high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.83 by $0.16. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The business’s revenue was up 23.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.13 earnings per share. analysts expect that Regeneron Pharmaceuticals Inc will post 13.55 EPS for the current year.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Morgan Stanley reissued an “equal weight” rating and issued a $490.00 target price (up from $450.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, October 6th. Jefferies Group reissued a “hold” rating and issued a $500.00 target price (up from $471.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, October 6th. SunTrust Banks reissued a “hold” rating and issued a $435.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, October 2nd. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, October 16th. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $471.11.

COPYRIGHT VIOLATION WARNING: “Regeneron Pharmaceuticals Inc (REGN) Shares Sold by Ingalls & Snyder LLC” was first published by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3147158/regeneron-pharmaceuticals-inc-regn-shares-sold-by-ingalls-snyder-llc.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.